Reactivation of the RIPK1/RIPK3/MLKL signalling platform by RIPK3 reconstitution can overcome necroptosis resistance in melanoma and therefore could be used as potential death-inducing targeted therapy against melanoma. This evidence concerns the gene RIPK3 and melanoma.